IMU Biosciences selects Waters to advance breakthrough AI immune mapping platform to transform early diagnosis, monitoring, and precision medicine.

{
  "signal_id": "fa4498bb-441d-43af-9121-161cee851ef9",
  "signal_type": "news",
  "signal_subtype": "signs_new_client",
  "detected_at": "2026-06-24T13:00:00+00:00",
  "company": {
    "name": "Waters",
    "domain": "waters.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/imu-biosciences-selects-waters-to-advance-breakthrough-ai-immune-mapping-platform-to-transform-early-diagnosis-monitoring-and-precision-medicine-302808585.html",
    "title": "IMU Biosciences selects Waters to advance breakthrough AI immune mapping platform to transform early diagnosis, monitoring, and precision medicine.",
    "ticker": "NYSE:WAT",
    "excerpt": "IMU Biosciences selects Waters to advance breakthrough AI immune mapping platform to transform early diagnosis, monitoring, and precision medicine.\n\nJun 24, 2026, 08:00 ET\n\n* IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time.\n* Waters Biosciences' technologies, including BD FACSDiscover(TM) and BD Rhapsody(TM) Instruments, will be used with IMU's AI analytics in research to deliver deeper, population-level disease insights.\n* Partnership supports IMU's expansion of its world-leading immune dataset through large-scale studies, establishing a new standard for immune profiling.\n\nMILFORD, Mass., June 24, 2026 /PRNewswire/ - Waters Corporation (NYSE: WAT) and IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform.\n\nThe partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies,[1] including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon(TM) Real Dyes, BD Rhapsody Instruments, and BD OMICS-One(TM) WTA Next Assay and Protein Panels, with IMU's HD analysis and...",
    "summary": "Waters Corporation signed new client Imubiosciences on Jun 24th '26.",
    "location": "Milford, Massachusetts, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://mma.prnewswire.com/media/2071755/Waters_Corporation_Logo.jpg?p=facebook",
    "confidence": 0.835,
    "published_at": "2026-06-24T13:00:00Z",
    "location_data": [
      {
        "city": "Milford",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-06-24",
    "article_sentence": "IMU Biosciences selects Waters to advance breakthrough AI immune mapping platform to transform early diagnosis, monitoring, and precision medicine.",
    "related_company_name": "Imubiosciences",
    "related_company_domain": "imubiosciences.com"
  }
}

curl https://signals.autobound.ai/v1/signals/fa4498bb-441d-43af-9121-161cee851ef9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"waters.com","limit":20}'